Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy

Masahide Okamoto, Mitsuhiro Okamoto, Koro Gotoh, Takayuki Masaki, Yoshinori Ozeki, Hisae Ando, Manabu Anai, Asami Sato, Yuichi Yoshida, So Ueda, Tetsuya Kakuma, Hirotaka Shibata*

Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan

Keywords
Anti-programmed cell death-1 antibodies, Fulminant type 1 diabetes, Nivolumab

*Correspondence
Hirotaka Shibata
Tel: +81-97-586-5793
Fax: +81-97-549-4480
E-mail address: hiro-405@cb3.so-net.ne.jp

J Diabetes Investig 2016; 7: 915–918
doi: 10.1111/jdi.12531

ABSTRACT
Anti-programmed cell death-1 (PD-1) antibodies are regarded as a risk factor for insulin-dependent diabetes mellitus as a side-effect. While a small number of cases have been reported, evidence remains limited. This is the first report of an Asian patient developing insulin-dependent diabetes during anti-PD-1 therapy. A 55-year-old euglycemic woman receiving nivolumab for malignant melanoma showed abrupt onset of ketonuria, and elevated levels of plasma glucose (580 mg/dL) and hemoglobin A1c (7.0%). Over the next 2 weeks, serum C-peptide levels fell below the limit of detection. Islet autoantibodies were negative, and the patient showed a human leukocyte antigen haplotype associated with type 1 diabetes. Anti-PD-1 therapy can cause rapid onset of insulin-dependent diabetes, possibly because of inappropriate activation of T cells. Human leukocyte antigen haplotypes might be related to the onset of this disease. Physicians should be aware of this serious adverse event and carry out routine blood glucose testing during anti-PD-1 therapy.

INTRODUCTION
Programmed cell death-1 (PD-1) is expressed on T cells, B cells and macrophages, and negatively regulates immune responses by binding to PD-1 ligands (PD-L1 or PD-L2). Most cancers escape from the host immune system as a result of the presence of those ligands. Nivolumab is a monoclonal antibody against the PD-1 receptor, achieving disinhibition of tumor-specific immune responses1. Although such immune checkpoint inhibitors have been shown to be highly useful against several types of cancer, descriptions of endocrinological adverse events have been accumulating. Some reports have described new-onset diabetes after anti-PD-1 pharmacotherapy2–5, but the evidence remains limited. We describe herein the case of a woman who developed fulminant type 1 diabetes during anti-PD-1 therapy, with some important findings that should contribute to elucidation of the pathogenesis.

CASE REPORT
A 55-year-old Japanese woman receiving nivolumab (2 mg/kg, once every 3 weeks) for malignant melanoma was referred to the Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University Hospital, Oita, Japan, as a result of hyperglycemia. She had no history of diabetes and no evidence of pancreatic metastases. She had been receiving nivolumab without combination with anti-T lymphocyte-associated antigen 4 antibody for 12 months at the time of referral, after 1 year of chemotherapy with dacarbazine, nimustine, cisplatin and tamoxifen. Blood glucose levels had been normal until the last blood examination, which was carried out 3 weeks before her referral. Although marked

Table 1 | Laboratory results of the patient

| Results |
| Glucagon (pg/mL) | 134 (70–174) |
| Amylase (U/L) | 36 (37–125) |
| Elastase1 (ng/dL) | 93 (<300) |
| Lipase (IU/L) | 31 (11–53) |
| Thyroid-stimulating hormone receptor antibody (IU/L) | <1.0 (<2.0) |
| Thyroglobulin antibody (IU/mL) | 10.9 (<28) |
| Thyroid peroxidase antibody (IU/mL) | 5.9 (<16) |
| Antipituitary antibody | (–) |
| Antinuclear antibody | (–) |
| Time-series data of serum CPR (ng/mL) | (0.61–2.09) |

| Day 0 | 1.0 |
| Day 2 | 0.7 |
| Day 7 | 0.3 |
| Day 17 | <0.1 |

Normal ranges given in parentheses where appropriate. CPR, C-peptide.
| Literature no. | Literature | Case no. | Age/sex | Diagnosis | Pertinent history | Other chemotherapies | Anti-PD-1 drug | Time after anti-PD-1 drug (months) | Islet cell autoantibodies | HLA | Other immune-related symptoms | Anti-PD-1 presence |
|---------------|------------|----------|---------|-----------|------------------|---------------------|-----------------|---------------------------------|--------------------------|-------|-----------------------------|------------------|
| 1             | Okamoto et al. | 55 F (Japanese) | Malignant melanoma | Dyslipidemia, gastric ulcer | Nivolumab | (–) Ketonuria | 580 mg/dL | Diabetes presentation | CPR and glucose | 12 months | GAD (–), CA (–), A2 (–), ZnT8 (–) | DRB1*0405, DQB1*0601 |
| 2             | Hughes et al. | 55 F (Not listed) | Malignant melanoma | Autoimmune thyroid disease, remote smoker | Nivolumab | Ipilimumab, prednisone | 580 mg/dL | Diabetes presentation | CPR and glucose | 5 months | GAD (–), CA (–), A2 (–), ZnT8 (–) | DRB1*0404, DQB1*0602 |
| 3             | Hughes et al. | 63 M (Not listed) | Renal cell carcinoma | Hypertension | Nivolumab | None | 360 mg/dL | Diabetes presentation | CPR and glucose | 1 month | DRB1*0405, DQB1*0301 | A2.1+ | |
| 4             | Hughes et al. | 63 M (Not listed) | Renal cell carcinoma | Hypertension | Pembrolizumab | None | 70 mg/dL | Diabetes presentation | CPR and glucose | 4 months | GAD (–), CA (–), A2 (–), ZnT8 (–) | DRB1*0404, DQB1*0301 |
| 5             | Hughes et al. | 58 M (Not listed) | Small-cell lung cancer | Type 2 diabetes mellitus | Pembrolizumab | None | 360 mg/dL | Diabetes presentation | CPR and glucose | 1 week | GAD (–), CA (–), A2 (–), ZnT8 (–) | DRB1*0404, DQB1*0301 |
| 6             | Hughes et al. | 54 F (Not listed) | Malignant melanoma | Autoimmune thyroid disease, psoriasis | Pembrolizumab | Ipilimumab | 450 mg/dL | Diabetes presentation | CPR and glucose | 6 months | GAD (–), CA (–), A2 (–), ZnT8 (–) | DRB1*0404, DQB1*0301 |
| 7             | Martin-Liberal et al. | 54 F (Not listed) | Malignant melanoma | Asthma | Pembrolizumab | Ipilimumab | 706 mg/dL | Diabetes presentation | CPR and glucose | 3 weeks | GAD (–), CA (–), A2 (–), ZnT8 (–) | DRB1*0404, DQB1*0301 |
| 8             | Mellan et al. | 70 M (Not listed) | Adenocarcinoma of the lung | Not listed | Pembrolizumab | Ipilimumab | 706 mg/dL | Diabetes presentation | CPR and glucose | 15 weeks | GAD (–), CA (–), A2 (–), ZnT8 (–) | DRB1*0404, DQB1*0301 |
| 9             | Mellan et al. | 66 F (Not listed) | Squamous cell carcinoma of the skin | Not listed | Pembrolizumab | Ipilimumab | 706 mg/dL | Diabetes presentation | CPR and glucose | 7 weeks | GAD (–), CA (–), A2 (–), ZnT8 (–) | DRB1*0404, DQB1*0301 |
| 10            | Gaudy et al. | 44 F (Caucasian) | Malignant melanoma | Type 1 diabetes mellitus | Pembrolizumab | Ipilimumab | 400 mg/dL | Diabetes presentation | CPR and glucose | 5 weeks | GAD (–), CA (–), A2 (–), ZnT8 (–) | DRB1*0404, DQB1*0301 |

Ab, antibodies; CPR, C-peptide; DKA, diabetic ketoacidosis; F, female; GAD, glutamic acid decarboxylase; HbA1c, hemoglobin A1c; HLA, human leukocyte antigen; IA-2, insulinoma-associated antigen-2; IA2, insulin autoantibody; M, male; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; ZnT8, zinc transporter 8.
hyperglycemia (580 mg/dL) and ketonuria had been noted at the first visit to our department, hemoglobin A1c level was relatively low (7.0%), suggesting rapid onset. The short period from onset to ketosis, extreme hyperglycemia and relatively low hemoglobin A1c level suggested fulminant type 1 diabetes. Findings at onset, such as serum C-peptide level (1.0 ng/mL) and urinary C-peptide excretion (12.6 μg/day), did not meet the diagnostic criteria for fulminant type 1 diabetes, but serum C-peptide levels dropped to below the limit of detection over the next 2 weeks, and glucagon tolerance testing showed complete depletion of insulin. As treatment for fulminant type 1 diabetes, multiple daily injections of insulin were started. Negative results were obtained for all islet autoantibodies (glutamic acid decarboxylase, insulinoma-associated antigen-2, insulin autoantibodies and zinc transporter 8), and further investigation revealed the DRB1*04:05-DQB1*04:01 human leukocyte antigen (HLA) haplotype, which is strongly associated with autoimmune type 1 diabetes in Japan. No blood examination findings or symptoms suggested acute viral infection before onset, and pancreatic enzyme levels at onset were not elevated (Table 1). Computed tomography showed mild atrophy of the pancreas, and endoscopic ultrasonography showed several findings generally seen in early chronic pancreatitis, namely hyperechoic foci and strands, lobularity, and cysts. Although those findings are often seen among individuals with heavy intake of alcohol, the patient had no history of drinking. Nivolumab treatment was resumed 1 month after the patient’s referral, and no further side-effects have been observed to date. Islet autoantibodies have remained negative, and insulin secretion has remained depleted as of 3 months after onset. Treatment with multiple insulin injections is ongoing.

DISCUSSION
The present report described a case of new-onset diabetes with anti-PD-1 therapy that showed a rapid fall into insulin-dependence. Onset was considered to be associated with the pharmacotherapy, as no other potential factors or causes (e.g., family history, irregular lifestyle, viral infection, pancreatic metastasis of the cancer or drugs other than nivolumab) could be identified. Our search of the literature found four reports (8 cases) of onset or worsening of diabetes in association with anti-PD-1 therapies (not limited to nivolumab), and all except one of those cases presented with diabetic ketoacidosis or ketonuria followed shortly thereafter by insulin-dependence. Considering the rapid onset, severity and potential mortality of those situations, routine measurement of both hemoglobin A1c and blood glucose levels is warranted after starting administration of anti-PD-1 antibodies. In the present case, we might have observed the very early stage of fulminant type 1 diabetes, considering that the patient was not completely insulin-dependent for the first few days after onset.

In the present case, all results for islet autoantibodies were negative. Half of the previously reported patients who developed insulin-dependent diabetes after anti-PD-1 therapy likewise showed no detectable autoantibodies (Table 2). The pathogenesis in these patients thus seems to differ at least partly from that of conventional autoimmune type 1 diabetes involving islet autoantibodies. Ansari et al. found no correlation between insulin autoantibody levels and development of diabetes with blockade of the PD-1–PD-L1 pathway in mice, and some mice developed diabetes despite the apparent absence of autoantibodies.

In contrast, reduced activity of PD-1 is apparently common to both conventional autoimmune type 1 diabetes and anti-PD-1 therapy-related diabetes. Fujisawa et al. recently showed a reduction in PD-1 expression on T cells in type 1 diabetes compared with other types of diabetes. Perri et al. also suggested that lower expression of PD-1 on T cells causes inappropriate activation of those cells in insulin-dependent diabetes. Anti-PD-1 drugs could produce a similar situation, and PD-1 reduction might cause inappropriate activation of T cells resulting in autoimmune responses against pancreatic β-cells.

Human leukocyte antigen typing in this case showed haplotype DRB1*04:05-DQB1*04:01, which is the haplotype most closely associated with autoimmune or fulminant type 1 diabetes in Japan. Reported cases to date have also shown high-risk HLA genotypes for autoimmune diabetes (Table 2). Considering these findings, HLA could be involved in the onset of insulin-dependent diabetes with anti-PD-1 therapy. Autoimmune diabetes might develop when anti-PD-1 drugs are given to at-risk patients, through imbalanced activation and inhibition of T cells, although the underlying mechanisms remain unclear. Biomarkers predictive of anti-PD-1 therapy-related diabetes have yet to be clarified, but HLA haplotypes could be one such biomarker. Further accumulation of cases and evidence is required.

Anti-PD-1 therapy can cause insulin-dependent diabetes that develops and progresses rapidly in a manner differing from conventional autoimmune diabetes, possibly through inappropriate activation of T cells. These cases might not present with autoantibodies to islet cells. HLA haplotypes might be related to disease onset. Physicians should be aware of this serious adverse event, and carry out routine blood testing during anti-PD-1 therapy. Further studies are required to elucidate the pathogenesis and background factors for this form of diabetes.

DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Deeks ED. Nivolumab: a review of its use in patients with malignant melanoma. Drugs 2014; 11: 1233–1239.
2. Mellati M, Eaton KD, Brooks-Worrell BM, et al. Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes. Diabetes Care 2015; 9: e137–138.
3. Martin-Liberal J, Furness AJ, Joshi K, et al. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 2015; 6: 765–767.

4. Hughes J, Vudattu N, Szol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015; 4: e55–57.

5. Gaudy C, Clévy C, Monestier S, et al. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 2015; 11: e182–183.

6. Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 2000; 5: 301–307.

7. Kawabata Y, Ikegami H, Awata T, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 2009; 12: 2513–2521.

8. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 1: 63–69.

9. Fujisawa R, Haseda F, Tsutsumi C, et al. Low programmed cell death-1 (PD-1) expression in peripheral CD4+ T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol 2015; 3: 452–457.

10. Perri V, Russo B, Crinò A, et al. Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus. Int J Mol Sci 2015; 9: 22584–22605.